We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Protagonist

News List

Press Release Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications FirstWordPharma
December 03, 2021
Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the selection of PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on intervention of the Interleukin-23 (IL-23)...
Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists firstwordpharma
July 29, 2021
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced its entry into an amended collaboration agreement (the "Restated Agreement") with Janssen Biotech, Inc.manufacture and commercialization.
Protagonist Therapeutics Initiates PTG-200 Phase 1 Trial americanpharmaceuticacreview
November 10, 2017
Protagonist Therapeutics announced the initiation of dosing in a Phase I healthy volunteer study of PTG-200, a potential first-in-class, gastrointestinal-restricted, oral peptide interleukin (IL)-23 receptor antagonist.